Home / Europe / Belgium / Life Sciences & Healthcare

Life Sciences & Healthcare

With over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences and healthcare business. We work with and have established long-term relationships with the top 100 lifesciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. As members and partners of major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EFPIA and EUCOMED we help shape the legal frameworks impacting the lifesciences and healthcare sectors. 

We regularly advise our clients on their day-to-day operational needs such as, patent enforcement, commercial and clinical trial agreements, protection of privacy and trade secrets, e-health, support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement as well as regulatory advice. 

Equally, when you need specialist advice in the area of lifesciences and healthcare for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

"Very hands-on knowledge and ability to provide very practical examples to the business. Feedback received was really what we needed, being very hands on, easy to understand feedback to specific practical questions."

Feedback from a client about the department - Legal 500, 2022

"CMS' cross-practice collaboration and multilingual capabilities make it a popular choice for a varied roster of pharmaceutical heavyweights, industry associations and hospital groups. The team is especially renowned for its public procurement capabilities, working with some of the largest Europe-wide governing bodies on high-profile, cross-border projects. Joint practice heads Bruno Fonteyn and Virginie Dor are noted for their expertise in health sector regulation and EU-wide health and social care procurement mandates, respectively."

Legal 500, 2022

Feed

12/07/2024
One year of Belgian foreign direct investment screening: state of play
On 1 June 2022, following the adoption of Regulation (EU) 2019/452 of 19 March 2019 establishing a framework for screening foreign direct investments in the EU, the various Belgian competent governments...
11/07/2024
Cannabis law and legislation in Belgium
Medical use In principle, the cultivation, import, sale and possession of (medicinal or recreational) cannabis is not allowed under Belgian law. An exception is made for the cultivation of hemp with a...
02/07/2024
Belgium ends merger control in the hospital sector
Following a long arm wrestling with the Belgian Competition Authority (BCA), the Belgian legislator adopted on 28 March 2024 a law, which finally excludes hospitals from merger control under the Belgian...
26/06/2024
Updated CMS Expert Guide to Cannabis law and legislation
CMS Expert Guide on cannabis law and legislation gives stakeholders detailed and updated information on the latest developments in cannabis regulation in key markets.  The Guide now covers 33 jurisdictions...
13/06/2024
What’s in a name? The use of a product code in a clinical trial protocol...
The use of product or sponsor codes in clinical trial related documents is common practice in the pharmaceutical space. However, such codes may not always be sufficient to disregard a publication as relevant...
21/05/2024
Consultation of the European Commission on Vifor's commitments concerning...
In response to the Preliminary Assessment stating the potential abuse of its dominant position, Vifor proposed several commitments to rectify the potential competition law infringement. The European Commission...
16/05/2024
A broader interpretation of "substance or composition" - good news for...
A recent decision from the EPO Boards of Appeal (T 1252/20) potentially paves the way for more diverse products to be patentable in Europe using the medical use claim format.The back­ground:Art­icle 53(c)...
11/04/2024
Navigating clinical trial disclosures: No reasonable expectation of success...
Recent EPO Board of Appeal decision T 1437/21 adds to a growing number of decisions concerning the patentability of second or further medical use inventions where the prior art relates to a clinical trial...
25/03/2024
Patentability of inventions relating to diagnostic methods at the EPO
Under Article 53(c) of the European Patent Convention (EPC), diagnostic methods practised on the human or animal body are excluded from patentability. The purpose behind this exclusion is to avoid patent...
30/01/2024
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...
09/01/2024
Belgian Competition Authority confirms jurisdiction over hospital mergers
Until recently, the hospital sector has escaped the attention of the Belgian Competition Authority (BCA).When the Belgian legislator, through the law of 28 February 2019 required hospitals to create loc­al-re­gion­al...
08/01/2024
Adapting to the new EU Data Act: implications for medical devices and other...
In recent years, the European Commission developed a European data strategy, which aims to create a single European market in which data can circulate freely. As the European Commission has emphasized...